Cristian-Virgil L.
- Country
- Romania
- Department
- Oncology
Research Overview
- Efficacy and Safety of REGN7508 for Primary Prophylaxis of Cancer-Associated Thrombosis in Patients with Solid Tumors Undergoing Cancer Treatment
- Phase 3 Randomized Trial of Eftilagimod Alfa, Pembrolizumab, and Chemotherapy in Advanced/Metastatic Non-Small Cell Lung Cancer Patients
- Efficacy and Safety of RLY-2608 Plus Fulvestrant Versus Capivasertib Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
Data & Insights
Has run more than one trial at 67 of 263 partner sites.
Specializations
Lung Cancer Treatment
The investigator specializes in treating advanced and metastatic non-small cell lung cancer (NSCLC), with particular focus on developing innovative therapeutic combinations.
- Immunotherapy Integration
- Combined Treatment Approaches
- Late-stage Cancer Management
Primary research interests include exploring novel therapeutic strategies for patients with advanced lung cancer using immunotherapy combinations.
Immunotherapy Research
Areas of expertise include the study of immune checkpoint inhibitors and novel immunotherapeutic agents in oncology treatment protocols.
- Novel Immunotherapeutic Agents
- Treatment Response Assessment
- Patient Selection Strategies
The investigator focuses on evaluating innovative immunotherapy combinations for improving treatment outcomes in lung cancer patients.
Therapeutic Innovation
Key interests encompass the development of combination therapy approaches that integrate standard treatments with emerging therapeutic agents.
- Treatment Protocol Development
- Clinical Efficacy Assessment
- Therapeutic Strategy Optimization
Research activities center on evaluating the effectiveness of combined treatment modalities in advanced cancer care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.